The future of clinical research depends on people just as much as strong systems and processes. Learn what makes great ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...

FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.

Jo Varshney, PhD, DVM, discusses how VeriSIM Life’s innovative approach leverages artificial intelligence and multispecies ...

The integration of Oracle Argus enables QPS to better capture, manage, and report adverse events for regulatory requirements.

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible ...

The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...

The MarketWatch News Department was not involved in the creation of this content. Xtalks Life Science Podcast Wraps Up 2025 with Deep Dives into Drug Development, Regulation, Clinical Trials and ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...